Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

1.

Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma.

Coleman EA, Coon SK, Kennedy RL, Lockhart KD, Stewart CB, Anaissie EJ, Barlogie B.

Oncol Nurs Forum. 2008 May;35(3):E53-61. doi: 10.1188/08.ONF.E53-E61.

PMID:
18467280
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Effects of exercise on fatigue, sleep, and performance: a randomized trial.

Coleman EA, Goodwin JA, Kennedy R, Coon SK, Richards K, Enderlin C, Stewart CB, McNatt P, Lockhart K, Anaissie EJ.

Oncol Nurs Forum. 2012 Sep;39(5):468-77. doi: 10.1188/12.ONF.468-477.

PMID:
22940511
[PubMed - indexed for MEDLINE]
3.

Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.

De Rosa L, Anghel G, Pandolfi A, Riccardi M, Amodeo R, Majolino I.

Int J Hematol. 2004 Jan;79(1):85-91.

PMID:
14979484
[PubMed - indexed for MEDLINE]
4.

Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.

Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.

Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404.

PMID:
15148493
[PubMed - indexed for MEDLINE]
5.
6.

Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.

Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C.

J BUON. 2007 Jan-Mar;12(1):41-4.

PMID:
17436400
[PubMed - indexed for MEDLINE]
7.

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

J Clin Oncol. 2010 May 1;28(13):2239-45. doi: 10.1200/JCO.2009.25.1835. Epub 2010 Apr 5.

PMID:
20368566
[PubMed - indexed for MEDLINE]
Free Article
8.

Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.

de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J.

Haematologica. 2006 May;91(5):621-7. Epub 2006 Apr 19.

PMID:
16627253
[PubMed - indexed for MEDLINE]
Free Article
9.

A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.

Corso A, Arcaini L, Caberlon S, Zappasodi P, Mangiacavalli S, Lorenzi A, Rusconi C, Troletti D, Maiocchi MA, Pascutto C, Morra E, Lazzarino M.

Haematologica. 2002 Oct;87(10):1041-5.

PMID:
12368158
[PubMed - indexed for MEDLINE]
Free Article
10.

Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.

Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S, Tura S, Cavo M.

Leukemia. 2000 Jul;14(7):1310-3.

PMID:
10914557
[PubMed - indexed for MEDLINE]
11.

High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.

Long GD, Chao NJ, Hu WW, Negrin RS, Wong RM, Blume KG.

Cancer. 1996 Dec 15;78(12):2502-9.

PMID:
8952558
[PubMed - indexed for MEDLINE]
12.

[High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].

Shimokawa T, Kajiguchi T, Saito M, Kojima Y, Takeyama H.

Gan To Kagaku Ryoho. 2003 Feb;30(2):251-4. Japanese.

PMID:
12610874
[PubMed - indexed for MEDLINE]
13.

The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.

Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M.

Haematologica. 2004 Sep;89(9):1124-7.

PMID:
15377474
[PubMed - indexed for MEDLINE]
Free Article
14.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
[PubMed - indexed for MEDLINE]
Free Article
15.

Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.

Galli M, Nicolucci A, Valentini M, Belfiglio M, Delaini F, Crippa C, Barbui AM, Giussani U, Rambaldi A, Barbui T.

Haematologica. 2005 Dec;90(12):1643-9.

PMID:
16330437
[PubMed - indexed for MEDLINE]
Free Article
16.

Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients.

Martino M, Oliva E, Console G, Stelitano C, Fujo M, Messina G, Irrera G, Pucci G, Mandaglio R, Callea V, Nobile F, Iacopino P, Morabito F.

Support Care Cancer. 2005 Mar;13(3):182-7. Epub 2004 Oct 6.

PMID:
15480819
[PubMed - indexed for MEDLINE]
17.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.

Blood. 1999 Jan 1;93(1):55-65.

PMID:
9864146
[PubMed - indexed for MEDLINE]
Free Article
18.

[Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group].

Adam Z, Krejcí M, Bacovský J, Hejlová N, Kuca B, Svojgrová M, Franková H, Gumulec J, Janca J, Veprek K, Januska B, Lehanka F, Rezek Z, Praskac P, Cahová S, Vránová M, Papajík T, Králová E, Novotná J, Scudla V, Koza V, Drbal J, Faber E, Mareschová I, Hájek R, et al.

Vnitr Lek. 1998 Jul;44(7):400-8. Czech.

PMID:
9748876
[PubMed - indexed for MEDLINE]
19.

Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.

Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B.

Clin Lymphoma Myeloma. 2006 Nov;7(3):210-6.

PMID:
17229337
[PubMed - indexed for MEDLINE]
20.

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S.

Biol Blood Marrow Transplant. 2009 Jun;15(6):718-23. doi: 10.1016/j.bbmt.2009.02.011. Epub 2009 Apr 8.

PMID:
19450756
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk